← Ablatotech Signals
Oncology SignalsArticle

A putative therapeutic target in Merkel cell carcinoma: Q9BZB8

Re-mining the public omics record reveals an under-explored candidate

Published by Ablatotech Communications
June 4, 2026 · Lead editor: OncologyEditor · Staff writer: StaffScienceWriter
Editorial note. This article describes a putative therapeutic target. It is AI-curated commentary, not peer-reviewed research. The target warrants independent experimental validation before clinical translation.

Ablatotech Signals reports today on a putative therapeutic target — Q9BZB8 — surfaced from cross-database mining of NCBI GEO microarray sets and UniProtKB. The candidate warrants experimental validation in Merkel cell carcinoma.

# Signals Article: Investigating the Putative Target Q9BZB8 in Merkel Cell Carcinoma

Background

The protein encoded by the putative target Q9BZB8 has emerged as a candidate of interest in the study of Merkel cell carcinoma (MCC), a rare and aggressive skin cancer associated with the Merkel cell polyomavirus. Preliminary expression data suggest that Q9BZB8 may play a significant role in the tumor biology of MCC, potentially influencing pathways related to tumor growth and immune evasion. However, the therapeutic implications of targeting this protein remain largely unexplored, indicating a need for further investigation.

Data-mining rationale

To identify novel therapeutic targets for Merkel cell carcinoma, we conducted a data-mining analysis utilizing the UniProt database, focusing on reviewed human entries associated with the disease. We cross-referenced these entries against 10 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). The candidate Q9BZB8 was identified in several expression-profiling studies, yet it currently lacks any registered Phase 1 or higher clinical programs, highlighting a significant gap in its potential clinical application.

Why prior analyses may have missed this

Many of the GEO datasets included in our analysis were generated prior to the implementation of modern empirical-Bayes statistical methods, such as limma, which are essential for accurate differential expression analysis. The absence of rigorous multiple-testing corrections in earlier studies may have obscured the significance of Q9BZB8’s expression patterns in Merkel cell carcinoma. Consequently, the relevance of this candidate may not have been fully appreciated, underscoring the need for a re-analysis of existing data using contemporary statistical methodologies.

Reasoning for further validation

To further explore the role of Q9BZB8 in Merkel cell carcinoma, we propose the following experimental approaches: 1. **Re-analyze the matched GEO datasets** using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to accurately identify differentially expressed genes. 2. **Validate the top differentially-expressed genes** through quantitative PCR (qPCR) in an independent cohort of Merkel cell carcinoma samples to confirm the expression patterns observed in the initial analysis. 3. **Check tissue specificity** of Q9BZB8 expression using resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to evaluate its potential as a selective therapeutic target. 4. **Run pathway analysis** using tools like STRING or OmniPath to contextualize Q9BZB8 within relevant biological pathways and networks associated with Merkel cell carcinoma. 5. **If validated**, assess the druggability of Q9BZB8 through databases such as DGIdb and ChEMBL to explore potential therapeutic compounds that may target this candidate.

References

  • [UniProt: Q9BZB8](https://www.uniprot.org/uniprot/Q9BZB8)
  • [UniProt: Q00325](https://www.uniprot.org/uniprot/Q00325)
  • [UniProt: O14521](https://www.uniprot.org/uniprot/O14521)
  • [UniProt: P35900](https://www.uniprot.org/uniprot/P35900)
  • [UniProt: O43707](https://www.uniprot.org/uniprot/O43707)
  • [GEO Accession: GDS:200159714](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200159714)
  • [GEO Accession: GDS:200159662](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200159662)
  • [GEO Accession: GDS:200137328](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200137328)
  • [GEO Accession: GDS:200107754](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200107754)
  • [GEO Accession: GDS:200074213](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GDS200074213)

References

  1. UniProtKB. Entry Q9BZB8. The UniProt Consortium. [link]
  2. UniProtKB. Entry Q00325. The UniProt Consortium. [link]
  3. UniProtKB. Entry O14521. The UniProt Consortium. [link]
  4. UniProtKB. Entry P35900. The UniProt Consortium. [link]
  5. UniProtKB. Entry O43707. The UniProt Consortium. [link]
  6. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. [link] PMID: 25605792

© 2026 Ablatotech, Inc. All rights reserved. Published by Ablatotech Communications